dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Kutse

Sotsiaalministeerium · 3. oktoober 2019
Viit
1.4-4/2424-1
Registreeritud
3. oktoober 2019
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-4 Kutsed ja kirjavahetus rahvusvahelistel seminaridel, konverentsidel jt üritustel osalemiseks
Toimik
1.4-4/2019
Vastutaja
Heli Laarmann (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervise osakond)
Lahendamise tähtaeg
8. november 2019

Failid

  • 📎02_Scope and Purpose_ENG.pdf426 KB
  • 📎03_SC Provisional Agenda_ENG.pdf394 KB
  • 📎04_SC Provisional Programme_ENG.pdf509 KB
  • 📎1_EST Screening Conference invitation.pdf407 KB
  • 📎E-kiri.pdf419 KB

Sisu (failidest)

WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ WELTGESUNDHEITSORGANISATION Date: 02 October 2019 ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ REGIONAL OFFICE FOR EUROPE Ms Elen Ohov BUREAU RÉGIONAL DE L’EUROPE REGIONALBÜRO FÜR EUROPA Adviser ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co- Head office: operation Department UN City, Marmorvej 51, Ministry of Social Affairs DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1 Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 Email: [email protected] 10122 Tallinn Website: http://www.euro.who.int Estonia Our reference: Your reference: Notre référence: Votre référence: Unser Zeichen: Ihr Zeichen: См. наш номер: На Ваш номер: Dear Ms Ohov, WHO European Conference on Screening UN City, Copenhagen, Denmark, 11–12 February 2020 I have the honour to inform you that the WHO Regional Office for Europe will hold a conference on screening in Copenhagen, Denmark, on 11–12 February 2020, with the financial support of the German Government. The Conference is organized in the framework of a WHO European initiative aimed at improving decision-making related to screening practices to maximize benefits and minimize harms. It is a progressive effort to include all Member States of the WHO European Region following the 2019 WHO European Technical Consultation on Screening. The Conference will include experts, technical advisers and policy makers in the Region, and will be supported by a WHO Secretariat team from the global, regional and country levels. The Conference aims to discuss the harms and benefits of screening for noncommunicable diseases and other conditions across the life-course, in light of scientific evidence and country experiences. With supporting policy briefs, guidance documents, expert presentations and country experience, participants will exchange views on the most pressing challenges and cross-cutting issues regarding screening, such as legal, ethical and resource implications, as well as political, social, commercial and technological drivers of screening. I have the pleasure to invite you to nominate two participants from your country with technical background and experience in screening, who will be able to share your country experience in relation screening for noncommunicable diseases and through the life-course. The working languages will be English and Russian with simultaneous interpretation provided. Travel for participants will not be covered. This office can offer to arrange and pay for accommodation and a daily subsistence allowance for the duration of the meeting in accordance with our travel regulations if required. UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email: [email protected] DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int Denmark I look forward to receiving your nominations, with the name, functional title and address (including email) of the proposed participants. We will then communicate directly with the nominees. We would appreciate if you could reply directly to the Secretariat, NCD Integrated Prevention and Control of Noncommunicable diseases, email [email protected] at your earliest convenience, but no later than 8 November 2019, in order to plan adequate time for travel arrangements and related logistics. Dr Jill Farrington, Coordinator, is responsible for this event, and we would appreciate you addressing your reply to her. Sincerely yours, Dr Bente Mikkelsen Director, Division of Noncommunicable Diseases and Promoting Health through the Life-course Encls: Provisional agenda Scope and purpose Provisional programme Copy for information to: Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs, Suur-Ameerika 1, 10129 Tallinn, Estonia H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative, Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland H.E. Mr Märt Volmer, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark Ms Marge Reinap, Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn, Estonia –2– WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО WHO European Conference on Screening /02 UN City, Copenhagen, Denmark 23 September 2019 11–12 February 2020 Original: English Scope and purpose While there appears to be a growing trend in the WHO European Region towards more screening for noncommunicable diseases and health checks throughout the life-course, policy makers, health professionals and the public often seem unaware of the potential harms of screening, its cost and burden on the health system and the need for strong quality assurance. This Conference aims to increase the effectiveness of screening programmes within the Region, maximizing benefits and minimizing harms. Screening is defined as the presumptive identification of an unrecognized disease or condition in an apparently healthy, asymptomatic population by means of tests, examinations or other procedures that can be applied rapidly and easily to the target population.1 Such a definition covers a potentially broad range of population ‘checks’, covering a wide variety of conditions and ages. The primary aim of screening is to improve prognosis of the health condition through earlier intervention and management with the hope to reduce mortality and suffering from a disease. Depending on the nature of the health conditions and the modalities of the screening, however, benefits can vary considerably and in some cases be minimal or even null. Within the WHO European Region, countries are implementing screening programmes for a wide range of conditions throughout the life-course even though there is not a clear evidence-base for effectiveness. All screening has the potential to do harm2 and these harms - like benefits - depend on the health conditions considered and the modalities of the screening. For example, screening for prostate cancer has been shown to bring very limited benefit in terms of reduction of mortality while harms (notably over-diagnosis and over-treatment) have proven to be important even in the controlled context of randomized control trials3. On the other side of the spectrum, organized screening programs for cervical cancer have proven to bring major benefits (decreased incidence and decreased mortality) with minimal harms when quality is adequately assured4. Assessing the balance between harms and benefits is not straightforward however and for some conditions it remains largely unknown, making policy decisions on screening a particularly difficult exercise. Decision-making regarding screening implementation can be influenced by many cultural, economic and political factors, which in many occurrences overshadow evidence, even when those are solid and clear. 1 http://www.who.int/cancer/prevention/diagnosis-screening/screening/en/ 2 “All screening programmes do harm, some do good as well…”. See for example: Muir Gray JA, Patnick J, Blanks, RG. Maximising benefit and minimising harm of screening. BMJ 2008;336:480. 3 Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 Dec 6;155(11):762-71. 4 WHO 2014. Comprehensive cervical cancer control - A guide to essential practice http://www.who.int/cancer/publications/cervical-cancer-guide/en/ Scope and purpose page 2 Such practices raise questions regarding the amount of harm done to healthy individuals throughout the WHO European Region. This amount has not been quantified, nor has there been an evaluation of the amount of public resources invested in programs that don’t bring benefit, however both are suspected to be important. The WHO Regional Office for Europe has therefore undertaken an initiative to explore these issues further with a focus on NCDs and other conditions throughout the life-course. A WHO European Technical Consultation on Screening held on 26–27 February 2019 clarified the evidence available for various screening practices (including harms and benefits), the current screening practices taking place in European countries and the important divergence between evidence and practice. Publications and guidance produced as a result of this first consultation will be shared on the occasion of the present meeting. The 2019 consultation resulted also in identification of some cross-cutting issues and possible solutions that will be further explored during the present meeting. The purpose of the present meeting is to generate knowledge and provide tools to improve screening practices and policy decision-making related to screening. The meeting will take place over two days and involve a WHO Secretariat team from the global, regional and country levels, as well as policy makers from Member States, technical experts and WHO Collaborating Centres. Expert presentations and country experiences will highlight cross-cutting issues (such as political, social, commercial and technological drivers of screening, legal, ethical and resource implications of screening, health literacy and the role of civil society) and potential solutions for adequate decision-making and successful screening. The outcomes of the meeting will be a set of key messages supporting smart screening strategies and practices. The working languages of the meeting will be English and Russian with simultaneous interpretation provided. WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО WHO European Conference on Screening /03 UN City, Copenhagen, Denmark 23 September 2019 11–12 February 2020 Original: English Provisional agenda 1. Opening session 2. Adoption of agenda and programme 3. Reflection from the 2019 Technical Consultation 4. Good principles of screening 5. Successes and challenges in screening 6. Applying good screening principles in practice 7. Health literacy and the role of civil society 8. Political, social, commercial and technological drivers 9. Scaling up effective and evidence-based screening 10. Legal, ethical and resource implications of screening 11. Closing Saatja: EURO NCD <[email protected]> Saadetud: 03.10.2019 09:47 Adressaat: Elen Ohov <[email protected]> Koopia: Triin Uusberg <[email protected]>; SM Info <[email protected]>; <[email protected]>; <[email protected]>; REINAP, Marge <[email protected]> Teema: EST: Invitation for nominations: WHO European Conference on Screening, UN City, Copenhagen, Denmark, 11–12 February 2020 Manused: 1_EST Screening Conference invitation.pdf; 02_Scope and Purpose_ENG.pdf; 03_SC Provisional Agenda_ENG.pdf; 04_SC Provisional Programme_ENG.pdf Dear Ms Ohov, Please find attached to this email an invitation to nominate candidates to attend the above mentioned Conference which will take place 11-12 February, 2020. We would appreciate to receive nominations no later than 8 November 2019. Please respond directly to this email, attention Dr Jill Farrington, who is responsible for this event Sincerely yours Secretariat, NCD Integrated Prevention and Control of Noncommunicable diseases On behalf of Dr Bente Mikkelsen Director, Division of Noncommunicable Diseases and Promoting Health through the Life-course WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО WHO European Conference on Screening /04 UN City, Copenhagen, Denmark 23 September 2019 11–12 February 2020 Original: English Provisional programme Tuesday, 11 February 2020 08:00–09:00 Registration 09:00–10:30 Plenary 1: Opening and introduction Opening Introduction to the programme and expected outcomes Reflections on the WHO European Technical Consultation on Screening Overview of outcomes and events since What are good principles of screening? Presentation of guide, policy brief and other publications 10:30–11:00 Coffee break and photo 11:00–12:30 Plenary 2: Successes and challenges in screening A panel of policymakers from countries share their experience 12:30–13:30 Lunch break 13:30–15:00 Parallel sessions A: Applying good screening principles in practice Expertise, experience and examples of implementing organized, evidence-based screening programmes, with sessions to include governance, quality assurance, monitoring and evaluation. 15:00–15:30 Coffee break 15:30–17:00 Plenary 3: Health literacy and the role of civil society Panel of perspectives 17:00–17:15 Closing of Day 1 17:30 Reception Provisional programme Page 2 Wednesday, 12 February 2020 09:00–10:30 Feedback from Day 1 Plenary 4: Political, social, commercial and technological drivers of screening Presentations and discussion 10:30–11:00 Coffee break 11:00–12:30 Parallel sessions B: Scaling up effective and evidence-based screening Evidence and experience in implementing screening programmes in countries, with topics likely to focus on non-cancer screening examples in particular 12:30–13:30 Lunch break 13:30–15:00 Plenary 5: Legal, ethical and resource implications of screening Presentations and discussion 15:00–15:30 Coffee break 15:30–17:00 Plenary 6: Conclusions and next steps Rapporteur’s report Facilitated discussion Conclusions Closing
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel